E-Mail
Several weeks following the publication of the large real-world Covid-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard University in the
New England Journal of Medicine (NEJM), additional results focusing on vaccine effectiveness in specific sub-populations have now been published.
While the original publication demonstrated the effectiveness of the Pfizer-BioNTech mRNA vaccine in the general population, outstanding questions remained regarding vaccine effectiveness in specific sub-populations of interest, including the elderly, multi-morbid individuals, and individuals with specific prevalent chronic conditions.
The new study also took place in Israel and evaluated data on approximately 1,400,000 Clalit members, with extended follow-up time compared to the previous study, and additional subpopulations. The advanced methodologies employed meticulous individual matching techniques to enable an as-clean-as-possible analysis
Researchers examine effectiveness of Pfizer vaccine against COVID-19
A major study, conducted in collaboration with researchers from Harvard University, examined data on 600,000 vaccinated individuals in Israel, along with 600,000 matched unvaccinated controls.
Two doses of Pfizer/BioNTech vaccine reduced symptomatic COVID-19 by 94% and severe disease by 92%; Single-dose reduced symptomatic COVID-19 by 57% and severe disease by 62%; Vaccine effectiveness was found to be similar across age groups; B.1.1.7 variant became dominant in Israel during the study period.
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world s largest integrated health record databases to examine the effectiveness of the Pfizer vaccine against COVID-19.
Pfizer-BioNTech shot could help end pandemic, Israel study shows Sorry, but your browser needs Javascript to use this site. If you re not sure how to activate it, please refer to this site: https://www.enable-javascript.com/
A paramedic prepares a dose of the Pfizer-BioNtech COVID-19 vaccine in Beit Shemesh, Israel, on Monday. | AFP-JIJI
Bloomberg Feb 25, 2021
Pfizer Inc. and BioNTech SE’s COVID-19 vaccine was overwhelmingly effective against the virus in a study that followed nearly 1.2 million people in Israel, results that public-health experts said show that immunizations could end the pandemic.
Two doses of the vaccine prevented 94% of COVID-19 cases in 596,618 people vaccinated between Dec. 20 and Feb. 1, about one-quarter of whom were over the age of 60, teams from the Clalit Research Institute and Harvard University reported in a study published Wednesday in the New England Journal of Medicine.
Covid-19: Israeli Study Confirms Efficacy of BNT162b2 Vaccine physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.
E-Mail
The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world s largest integrated health record databases to examine the effectiveness of the Pfizer vaccine against COVID-19. The study provides the first large-scale peer-reviewed evaluation of the effectiveness of a COVID-19 vaccine in a nationwide mass-vaccination setting. The study was conducted in Israel, which currently leads the world in COVID-19 vaccination rates.
The results of this study validate and complement the previously reported findings of the Pfizer/BioNTech Phase-III randomized clinical trial, which focused on symptomatic infections, and which, with 21,720 vaccinated individuals, could not precisely assess vaccine effectiveness against severe disease in the fully vaccinated. The present study s large size allows a more detailed assessment of the vaccine s effectiveness in preventing a wider range of outcomes, across different time periods and populati